Acasti Pharma Inc. (ACST)

NASDAQ: ACST · IEX Real-Time Price · USD
3.400
0.00 (0.00%)
At close: Mar 27, 2024, 4:00 PM
3.270
-0.130 (-3.82%)
Pre-market: Mar 28, 2024, 8:06 AM EDT

Total Valuation

Acasti Pharma has a market cap or net worth of $31.96 million. The enterprise value is $13.53 million.

Market Cap 31.96M
Enterprise Value 13.53M

Important Dates

The last earnings date was Monday, February 12, 2024, before market open.

Earnings Date Feb 12, 2024
Ex-Dividend Date n/a

Share Statistics

Acasti Pharma has 9.40 million shares outstanding.

Shares Outstanding 9.40M
Owned by Insiders (%) 16.02%
Owned by Institutions (%) 6.09%
Float 6.86M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 0.67
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 15.19, with a Debt / Equity ratio of 0.00.

Current Ratio 15.19
Quick Ratio 14.73
Debt / Equity 0.00
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage 154.76

Financial Efficiency

Return on equity (ROE) is -58.90% and return on invested capital (ROIC) is -73.66%.

Return on Equity (ROE) -58.90%
Return on Assets (ROA) -50.60%
Return on Capital (ROIC) -73.66%
Revenue Per Employee n/a
Profits Per Employee -$1.21M
Employee Count 32
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax -7.21M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +31.23% in the last 52 weeks. The beta is 1.49, so Acasti Pharma's price volatility has been higher than the market average.

Beta (1Y) 1.49
52-Week Price Change +31.23%
50-Day Moving Average 2.97
200-Day Moving Average 2.60
Relative Strength Index (RSI) 62.32
Average Volume (30 Days) 26,977

Short Selling Information

Short Interest 6,587
Short Previous Month 23,160
Short % of Shares Out 0.27%
Short % of Float n/a
Short Ratio (days to cover) 0.84

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -35.01M
Pretax Income -35.69M
Net Income -38.77M
EBITDA -35.91M
EBIT -35.93M
Earnings Per Share (EPS) -$3.73
Full Income Statement

Balance Sheet

The company has $18.45 million in cash and $17,631 in debt, giving a net cash position of $18.43 million or $1.96 per share.

Cash & Cash Equivalents 18.45M
Total Debt 17,631
Net Cash 18.43M
Net Cash Per Share $1.96
Equity / Book Value 47.52M
Book Value Per Share 5.06
Working Capital 18.45M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$9.97 million and capital expenditures $74,931, giving a free cash flow of -$9.89 million.

Operating Cash Flow -9.97M
Capital Expenditures 74,931
Free Cash Flow -9.89M
FCF Per Share -$0.86
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Acasti Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -54.75%
Shareholder Yield -54.75%
Earnings Yield -121.33%
FCF Yield -30.96%

Analyst Forecast

The average price target for Acasti Pharma is $6.00, which is 76.47% higher than the current price. The consensus rating is "Strong Buy".

Price Target $6.00
Price Target Difference 76.47%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on July 10, 2023. It was a reverse split with a ratio of 1:6.

Last Split Date Jul 10, 2023
Split Type Reverse
Split Ratio 1:6

Scores

Altman Z-Score n/a
Piotroski F-Score 2